We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




High-Value Practice Reduces Wasteful Blood Transfusions

By LabMedica International staff writers
Posted on 05 Dec 2017
Although blood transfusion is a lifesaving therapy for some patients, transfusion has been named one of the top five overused procedures in hospitals in the USA.

As unnecessary transfusions only increase risk and cost without providing benefit, improving transfusion practice is an effective way of promoting high-value care. More...
Most high-quality clinical trials supporting a restrictive transfusion strategy have been published in the past five to 10 years, so the value of a successful patient blood management program has only recently been recognized.

Experts at the Johns Hopkins Medical Institutions (Baltimore, MD, USA) and their colleagues analyzed data from randomized clinical trials comparing blood transfusion approaches and endorse recommendations for blood transfusions that reduce blood use to improve patient safety and outcomes. The clinical trials that were examined compared so-called liberal versus restrictive blood transfusions. Liberal transfusions are those given to patients with hemoglobin values of 9 to 10 g/dL, of blood volume, while restrictive transfusions are those given to patients with 7 to 8 g/dL. Many of the clinical trials examined by this team used the number of patients who died within a 30- to 90-day window post-transfusion as a measure of patient outcome.

Of the more than 8,000 patients included in eight clinical trials that were reviewed, there was no difference in mortality between liberal or restrictive transfusions. One clinical trial found an increased mortality associated with liberal transfusion, and occurrence of blood clots was increased in the liberal cohort in a study that involved traumatic brain injury patients. The team also found that the largest randomized trials reduced the amount of blood used by 40% to 65%. Earlier this year, the results of a four-year project to implement a blood management program across the Johns Hopkins Health System, reducing blood use by 20% and saving more than USD 2 million on costs over a year.

Stable adult patients, including critically ill patients, with hemoglobin levels of 7 g/dL or higher should not be transfused. Patients undergoing orthopedic or cardiac surgery, or patients with underlying heart disease with hemoglobin levels of 8 g/dL or higher should not be transfused. Patients who are stable and not actively bleeding should be transfused with a single unit of blood and then reassessed.

Steven M. Frank, MD, professor of anesthesiology and the lead investigator, said, “In summary, there is no benefit in transfusing more blood than necessary and some clinical trials actually show harm to patients. All this does is increase risks and cost without adding benefit.” The study was published on November 20, 2017, in the journal JAMA Internal Medicine.

Related Links:
Johns Hopkins Medical Institutions


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.